Pharmacological treatment of patients with MS : A retrospective study with focus on treatment with AEDs and polytherapy with other CNS active drugs by Beiske, Georg Anton Giæver
  
Pharmacological treatment of 
patients with MS  
 
A retrospective study with focus on 
treatment with AEDs and polytherapy with 
other CNS active drugs  
 
 
Georg Anton Giæver Beiske 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Master thesis in Pharmacy 
School of Pharmacy 
Faculty of Pharmaceutical Biosciences  
 
UNIVERSITY OF OSLO 
 
2013 
II 
 
 
 
 
 
 
 
 
  
III 
 
 
Pharmacological treatment of 
patients with MS 
 
A retrospective study with focus on 
treatment with AEDs and polytherapy with 
other CNS active drugs 
 
 
Georg Anton Giæver Beiske 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supervisors 
Cecilie Johannessen Landmark, PhD 
Hege Thoresen, Professor 
 
Master thesis in Pharmacy 
School of Pharmacy 
Faculty of Pharmaceutical Biosciences  
 
UNIVERSITY OF OSLO 
 
February 2013 
IV 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© Georg Anton Giæver Beiske, 2013 
Pharmacological treatment of MS patients 
http://www.duo.uio.no/ 
Trykk: Reprosentralen, Universitetet i Oslo 
V 
 
Acknowledgements 
 
I would like to express my special thanks to my supervisor Cecilie Johannessen Landmark. I 
am truly grateful for her guidance and knowledge, without which this project would not have 
been possible.  
I am also very thankful for everything my mother has taught me, and her involvement in this 
project. I am very proud to have taken part in a scientific study with her. 
My gratitude is also extended to Cecilie for her academic assistance and keen eye for details. 
Last, but not least I would like to thank Nelli for proofreading my thesis and Silje Andrea for 
her valued insights. 
 
 
  
VI 
 
 
VII 
 
Abstract 
 
MS patients are often suffering from chronic pain. Pain is a debilitating symptom and 
treatment is associated with undesirable adverse reactions, especially long-term treatment 
where tolerance and dependence issues are concerning. Therefore, antiepileptic drugs are 
frequently being used in the management of chronic pain. Antiepileptic drugs are among the 
most susceptible drugs to be involved in pharmacokinetic as well as pharmacodynamic 
interactions. MS patients often use several different types of CNS-active drugs, yet little 
research has been done to highlight potential polypharmacy issues. 
The aim of this study was to investigate the pharmacological treatment of MS patients at the 
rehabilitation centre for MS, Hakadal, Norway, with regards to current knowledge on 
polypharmacy, with particular focus on antiepileptic drugs. Medical records from 2009 to 
2011 were reviewed and an overview of drug dosages and combinations used by patients at 
MSSH was created. 
The present study demonstrated that one third of MS patients used either an AED 
(antiepileptic drug) or TCA (tricyclic antidepressant) and that one fifth used two or more. 
There was no difference in age, gender or degree of disability of the patients using these 
drugs. Polytherapy was widespread, with up to 19 concomitant drugs in use. Although the 
AEDs are well-known for their pharmacokinetic interactions, this is not of particular concern 
for MS patients since they mainly used newer AEDs (pregabalin and gabapentin) with little 
propensity to interact. Pharmacodynamic interactions are of greater concern since more than 
half of the patients used an opioid, a benzodiazepine or baclofen in addition to their 
AED/TCA therapy. One third of the patients were elderly and careful considerations 
regarding pharmacokinetics and possible excessive adverse reactions are of importance. More 
focus on individualisation of treatment by implementation of therapeutic drug monitoring of 
AEDs and TCAs and attention to potential pharmacodynamics interactions may be further 
treatment concerns. 
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1. Introduction 
1.1 Background 
Multiple Sclerosis (MS) is an inflammatory, neurodegenerative disease of the central nervous 
system. Prevalence varies throughout the world and Norway has a high prevalence of about 
150 per 100,000 (Torkildsen et al. 2007). 
MS treatment has received considerable attention in Norwegian press lately due to the high 
costs of newly approved drugs and even more expensive experimental treatment options 
(Bakke 2012). Treating a single patient with currently available disease-modifying drugs costs 
at least 200,000 NOK per year. An economic report on MS costs estimated a yearly cost to 
the Norwegian society of € 65,000 (≈477,000 NOK) per patient and a total of € 439 million 
(≈3,222 million NOK) for the entire Norwegian MS population (Svendsen et al. 2012). This 
fact, combined with the unsatisfactory nature of current MS treatment, displays the vast 
potential for improvement of treatment, both disease-modifying and symptomatic. 
MS patients are often suffering from chronic pain. Pain is a debilitating symptom and 
treatment is associated with undesirable adverse reactions, especially long-term treatment 
where tolerance and dependence issues are concerning. Therefore, antiepileptic drugs are 
frequently being used in the management of chronic pain. Antiepileptic drugs are among the 
most susceptible drugs to be involved in pharmacokinetic as well as pharmacodynamic 
interactions (Johannessen Landmark and Patsalos 2010). It is probable that MS patients use 
several different types of CNS active drugs, yet little research has been done to highlight 
potential polypharmacy issues. 
 
1.1.1 Centre for MS-Rehabilitation Hakadal, Norway – MSSH 
The centre is a tertiary centre founded in 1976 and a part of the sector for specialised 
healthcare in Norway. It is owned by the National Norwegian MS organisation and run as an 
independent non-profit business. Patient stays are funded by Norwegian health authorities. 
MSSH’s main goal is to be a professional resource centre and a key cooperative for health 
regions and personnel concerning MS treatment (mssh.no). 
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1.1.2 Aim of the study 
The aim of this study is to investigate the pharmacological treatment of MS patients at MSSH 
with regards to current knowledge on polypharmacy, with particular focus on antiepileptic 
drugs. It is therefore necessary to record and create an overview of drug dosages and 
combinations used by patients at MSSH. By comparing these results with recent international 
guidelines on treatment of neuropathic pain by antidepressants and antiepileptic drugs, we 
hope to reveal a potential for improvement in the pharmacological treatment of pain in MS 
patients.  
 
1.2 Multiple Sclerosis 
1.2.1 Diagnosis 
Multiple Sclerosis is an inflammatory autoimmune disease of the central nervous system. The 
disease was first defined by the French neurologist Jean-Martin Charcot in 1868. Charcot 
related plaques, areas of damaged myelin in the central nervous system, found during 
autopsies to their clinical manifestations (Clanet 2008). When diagnosing patients, Charcot 
had to rely solely on clinical findings. These days, the diagnosis of MS is usually made after 
both clinical and laboratory findings, including the use of an MRI (magnetic resonance 
imaging) scan. An MRI scan enhances the inflammation around the blood vessels caused by 
active lesions following a gadolinium injection, partly due to leakage of the 
blood−brain barrier.  Schumacker et al. defined two criteria for MS diagnosis in 1965, 
dissemination in time (DIT) and space (DIS) (Schumacker et al. 1965). Other possible 
diseases must also be eliminated before a definite MS diagnosis can be made. For example, in 
Norway and other countries with a known risk of tick bites, the cerebrospinal fluid should be 
tested to exclude Lyme’s disease. Dissemination in time refers to CNS lesions at different 
times, and dissemination in space means CNS lesions in different places in the nervous 
system. Clinically fulfilling these criteria requires at least two attacks (DIT) with different 
symptoms representing lesions at different places in the nervous system. If only one attack 
has been described clinically, an MRI scan at a later time can display a lesion at a different 
place, establishing DIT and DIS, without clinical manifestations of this second attack. An 
MRI scan of a new lesion after a three year follow-up is shown in figure 1. These criteria are 
still the mainstay for MS diagnosis. For further details on current MS diagnosis criteria, the 
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reader is referred to the latest review of the internationally established McDonald criteria 
published by the American Neurology Association (Polman et al. 2011). 
 (Bakshi et al. 2008) 
Figure 1. New juxtacortical lesion of 44–year–old–woman. A: Baseline; B: New lesion 3 years later; 
C: Subtract image of A and B diplays lesion clearly 
 
1.2.2 Epidemiology 
MS has a mean age of onset at about 30 years (Weinshenker et al. 1989). More women are 
affected than men (Duquette et al. 1992). Prevalence varies throughout the world with 
2 million patients affected globally, and northern Europe and America have the highest rates 
(Koch-Henriksen and Sorensen 2011). Norway has a high prevalence of about 150 per 
100,000 (Torkildsen et al. 2007). The incidence in Norway is about 300 new patient cases per 
year (Smestad et al. 2008). 
 
1.2.3 Pathophysiology 
MS comes in several forms, with distinct characteristics and prognosis representing variations 
in the underlying pathoetiology and pathophysiology. The most common division is based 
upon the status of disease progression, comprising three different groups (displayed in 
figure 2): Relapsing–Remitting MS (RRMS), Primary Progressive MS (PPMS) and 
Secondary Progressive MS (SPMS). MS patients are also divided by their age at disease 
onset, the typical groups are: early-onset MS (younger than 16; EOMS), adult-onset MS 
(between 16 and 50; AOMS) and late-onset MS (after 50; LOMS). Only 3 % of patients have 
an EOMS (Duquette et al. 1987) and 6 % have a LOMS (Weinshenker et al. 1989). 
4 
 
 
Figure 2. Disease-course of MS. PPMS (Primary Progressive MS); RRMS (Relapsing–Remitting MS); 
SPMS (Secondary Progressive MS) 
 
1.2.4 Relapsing–Remitting MS 
Approximately 85 % of MS patients initially have RRMS (Trapp and Nave 2008). RRMS is 
well-known for periods of alternating neurological disability and recovery. RRMS patients 
develop new, active “MS lesions”. Active lesions are lesions with active inflammation, which 
cause reversible oedema blocking the conduction of action potentials. This, in addition to 
demyelination throughout the CNS is a major contributor to temporary loss of function in 
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RRMS patients. There are a number of mechanisms activated to restore function to 
demyelinated axons. For example, redistribution of voltage-gated sodium channels along the 
demyelinated axolemma (Waxman 2006, Dutta and Trapp 2011). This restores action 
potential conduction in the axon at a reduced velocity. Finally, the axon is remyelinated after 
the oedema has resolved. 
Progressive axonal loss is the major cause of permanent neurological disability in MS. After 
immune-mediated breakdown of myelin the axon is vulnerable to the destructive processes of 
inflammation. Processes causing axonal transection are thought to include accumulation of 
amyloid precursor proteins, phosphorylation of axonal neurofilaments, glutamate-mediated 
excitotoxicity and release of proteolytic enzymes, matrix metalloproteases, cytokines, 
oxidative products and free radicals by activated immune and glial cells (Dutta and Trapp 
2011). Significant axonal loss has been seen in RRMS patients with short disease duration 
without permanent disabilities, displaying the fact that the brain has an ability to compensate 
for neuronal loss. It seems that a certain threshold of axonal loss must be reached before there 
are any clinical manifestations. RRMS patients develop SPMS once the brain no longer can 
compensate for neuronal loss (Nave and Trapp 2008). 
 
1.2.5 Primary and Secondary Progressive MS 
About 10 % of MS patients have a disease-course characterised by steady neurological 
deterioration without recovery, classified as PPMS. PPMS is associated with older age at 
onset than RRMS (Myhr et al. 2001). Most patients (90 %) with initial RRMS will, after 
25 years, experience the same steady decline in function without recovery, this is termed 
SPMS (Dutta and Trapp 2011). In contrast to RRMS patients, SPMS patients decline in 
function without signs of new lesions. The well-established explanation for this decline in 
function is a progressive loss of chronically demyelinated axons. PP/SPMS patients do not 
respond to immunomodulatory treatment in contrast to RRMS patients, supporting the theory 
of chronically demyelinated axons in PP/SPMS. 
 
1.2.6 Expanded Disability Status Scale – EDSS 
In 1983 John F. Kurtzke published the Expanded Disability Status Scale for evaluating the 
disability of MS patients (Kurtzke 1983). The EDSS is still the most commonly used tool for 
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numerically describing the disability status of MS patients in both treatment and natural 
history studies. To determine the EDSS score of a patient, a thorough neurological 
examination is required. The EDSS has been tested and validated internationally (Kurtzke 
2008). Please see appendix 6.1 for further details. 
 
1.2.7 Symptoms and comorbid disorders 
There is a fine line between symptoms and comorbid disorders in complicated autoimmune 
diseases such as MS, they can be overlapping and classification may be a matter of debate. 
Therefore, they are presented together without further discussion. 
 
Neuropathic pain 
Neuropathic pain was in 2011 defined by the International Association for the Study of Pain 
(IASP) as “pain caused by a lesion or disease of the somatosensory system” (Jensen et al. 
2011). Neuropathic pain is unrelated to any peripheral tissue injury. The pathophysiological 
mechanisms are poorly understood. Spontaneous firing of voltage-gated sodium channels, due 
to improper regulation and overexpression caused by release of hyperalgesic 
pro-inflammatory agents is thought to play a role (Chahine et al. 2005). Damaged sensory 
neurons can express α-adrenoceptors, thus responding to physiological sympathetic stimuli, 
which they normally would not. This phenomenon is described as sympathetically mediated 
pain (Rang et al. 2007).  
Neuropathic pain may be of central or peripheral origin. In multiple sclerosis, central 
neuropathic pain is defined as present if there is a central nervous system lesion regionally 
consistent with the pain distribution, but both nociceptive and peripheral neuropathic pain 
must be excluded (Osterberg et al. 2005). In a study of 364 MS patients, Osterberg et al. 
reported that 57.5 % had suffered from pain during their disease-course; 27.5 % suffered from 
central pain, 21 % from nociceptive, 2 % from peripheral neuropathic pain and 1 % was 
related to spasticity. 
Although pharmacological treatment of neuropathic pain is efficacious in most patients, 
complete pain-relief is difficult to achieve. Drugs commonly used have similar efficacy across 
the spectre of diseases causing neuropathic pain, except for trigeminus neuralgia, 
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radiculopathy and HIV neuropathy (Attal et al. 2010). Central pain, including trigeminus 
neuralgia, is most commonly experienced by MS patients. Currently available drugs for 
treating central pain include tricyclic antidepressants (TCA), antiepileptic drugs (AED), 
selective noradrenalin reuptake inhibitors (SNRI), cannabinoids and opioids. The European 
Federation of Neurological Societies (EFNS) guideline recommends carbamazepine as 
first-line treatment for trigeminal neuralgia and amitriptyline, pregabalin or gabapentin for 
central pain (Attal et al. 2010). The mechanisms of action and documentation on the use of 
the different drugs will be reviewed in more detail in section “1.3.3 Symptomatic treatment”. 
 
Epilepsy 
Epilepsy is defined as a neurological disorder and it is one of the most common ones 
worldwide; the global prevalence is 0.7 to 1 % (Elger and Schmidt 2008). An increased risk 
of developing epilepsy is related to several neurological diseases and syndromes. Koch et al. 
found 30 different studies with more than 50 patients which studied the epilepsy prevalence in 
different MS populations. The epilepsy prevalence varied between 0.6 and 8 %. In their 
review they pooled all the studies with a total of 19,804 MS patients and the frequency of 
epileptic seizures was estimated as 2.2 % (Koch et al. 2008). The prevalence of epilepsy in 
the general population is between 0.5 and 1 % (Sander 2003, Elger and Schmidt 2008). 
Increased risk of epilepsy in MS patients is widely accepted as true, the explanation for this, 
is, however, still not fully understood.  
 
Narcolepsy 
Sleep disorders are common among MS patients, prevalence estimates vary between 
25 and 54 % (Brass et al. 2010). Narcolepsy is particularly interesting, as it shares genetic risk 
factors with MS. Nearly all patients suffering from narcolepsy (95 %) and 50–60 % of MS 
patients express the DR2 haplotype (Caminero and Bartolome 2011). The narcolepsy 
prevalence in the general population in Europe is 3–5 for every 10,000 individuals. In a study 
of 116 patients with narcolepsy, MS was the fourth most common cause (n=10) (Nishino and 
Kanbayashi 2005). The fact that fatigue is so common among MS patients makes narcolepsy 
an important differential diagnosis for the physician to keep in mind. 
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Other symptoms and disorders 
Migraine, inflammatory bowel disease, irritable bowel syndrome, chronic lung disease and 
secondary osteoporosis have also been reported as more common among MS patients than the 
general population. Common MS symptoms beyond the scope of this thesis include spasms, 
fatigue, cognitive issues, depression and anxiety (Beiske 2009).  
 
1.3 Treatment of MS 
The different treatment options for MS are summarised in table 1. 
Table 1. Treatment of MS 
Treatment of MS Rationale Examples 
Attacks (RRMS only) Reduce impact of the attack methylprednisolone 
Disease-modifying (RRMS 
only) 
Reduce number of attacks 
and possibly slow 
progression of disability 
1
st
 line: Beta-interferons and                                  
glatiramer acetate 
2
nd
 line: Natalizumab and 
fingolimod 
3
rd
 line: mitoxantrone 
 
Symptomatic treatment is at least as important as disease-modifying treatment to reduce 
disease-burden and improve quality of life. Symptomatic treatment applies to all patients, 
regardless of their disease-course classification. Common treatment options for MS symptoms 
are listed in table 2. 
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Table 2. Symptomatic treatment options 
Symptomatic treatment Drug class Examples 
Anxiety Benzodiazepine Diazepam 
Spasms Antispasmodic 
Benzodiazepine 
AED 
Baclofen, botulinum toxin 
Clonazepam  
Pregabalin, gabapentin 
Depression SSRI 
SNRI 
TCA 
Escitalopram, paroxetine 
Venlafaxine 
Imipramine 
Insomnia Z-hypnotic Zopiclone, zolpidem  
Bladder dysfunction Muscarinic antagonists Solifenacin, tolterodine 
Migraine Triptan  
Ergot alkaloid 
Sumatriptan, rizatriptan 
Ergotamine 
Neuropathic pain AED 
Opioid 
TCA 
Gabapentin, pregabalin 
Tramadol, oxycodone 
Amitriptyline 
General pain Mild analgesic  
Opioid 
Paracetamol, ibuprofen 
Tramadol, codeine 
 
1.3.1 Treatment of attacks 
As described above, RRMS patients have periods of temporary neurological deterioration; 
these periods are commonly known as “attacks”. The attacks are caused by inflammation as a 
result of active lesions. The national guideline for MS treatment dictates that attacks with 
clinically significant decline in function should be treated with anti-inflammatory medications 
such as methylprednisolone. Possible infections must be ruled out and treatment should 
commence as soon as possible, preferably within one to two weeks (Myhr et al. 2010). 
 
1.3.2 Disease-modifying treatment 
Currently available disease-modifying drugs are only useful for treatment of RRMS. There 
are several available treatment options in Norway, divided in to three categories: 
first-, second- and third-line treatment. First-line treatment options are beta-interferons and 
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glatiramer acetate. These drugs have been used since the 1990s. Although they reduce attacks 
by about 30 %, any effect on permanent invalidity seems to be rather limited (Holmoy and 
Celius 2011). Flu-like symptoms and adverse reactions related to injection are common, since 
the drugs have to be injected on either a daily or weekly basis. Interferons have been shown to 
inhibit cytochrome P450 (CYP) enzyme activity, particularly interferon-alpha in treatment of 
patients with hepatitis C (Christensen and Hermann 2012). Previously interferon-alpha was 
also used in treatment of RRMS. Interferon-beta has not yet been shown to affect CYP 
metabolism in MS patients. 
The second-line treatment options are natalizumab and fingolimod. They cost twice as much 
as the first-line alternatives, approximately € 25,000 (≈200,000 NOK) per patient per year. 
Natalizumab is a monoclonal antibody administered at the hospital by monthly infusions. 
Fingolimod (sphingosine 1-phosphate receptor modulator) is available in tablets for daily 
administration. Natalizumab binds α-integrin-4, thereby blocking it from binding to its ligand. 
The net result is blockage of the peripherally activated immune cells’ migration across the 
blood–brain barrier. Natalizumab can cause a very rare and dangerous adverse reaction, 
progressive multifocal leukoencephalopathy (PML). The second-line treatments are approved 
for use in patients with active disease, after failing first-line treatment or for patients with a 
particularly rapid and debilitating disease-course (Myhr et al. 2010). 
Third-line treatment in Norway is chemotherapy (mitoxantrone). Only few patients currently 
receive this treatment, due to cardiotoxicity and risk of developing leukaemia. 
 
1.3.3 Symptomatic treatment 
MS patients suffer from a wide range of symptoms. Some symptoms are often treated 
efficaciously including pain, paroxysmal symptoms, spasticity, depression, bladder and sexual 
dysfunction. Other MS symptoms such as fatigue, cognitive dysfunction, ataxia, dysarthria, 
dysphagia, bowel dysfunction, visual loss and oculomotor symptoms lack evidence-based 
treatment options (Beiske 2009). Drugs with central effects often used for treatment of MS 
patients are especially relevant to this thesis and will be discussed in more detail below. An 
overview of pharmacological targets for relieving central pain is given in figure 3. 
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Figure 3. Pharmacological targets for relieving central pain (AED: antiepileptic drug; 
TCA: tricyclic antidepressant) 
 
Antidepressants 
The mainstay of pharmacological treatment of depression is in accordance with the 
monoamine hypothesis proposed by Schildkraut in 1965 (Rang et al. 2007). Antidepressant 
drugs fall in to one of the three following categories, inhibitors of monoamine uptake (TCAs, 
SSRIs and SNRIs), monoamine oxidase inhibitors (reversible MAO-A selective and 
irreversible unselective inhibitors) or atypical receptor-blocking agents (St. John’s wort, 
mianserin etc.) (Licinio and Wong 2005). The mechanisms of action of drugs in the latter 
category are poorly understood. It takes at least two weeks before any antidepressant effects 
are seen, even though the drugs immediately exhibit their effects on the receptors.  
Interestingly, the TCAs have also been proven efficacious in treatment of neuropathic pain. 
A recent Cochrane review on the use of antidepressants in the treatment of neuropathic states 
that amitriptyline exhibits the best documented effect on neuropathic pain. Furthermore its 
NNT (number–needed–to–treat) was calculated to 3.1 (95 % CI 2.5 to 4.2) (Saarto and Wiffen 
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2007). The specific mechanism for TCAs’ pain relieving effect has remained elusive, 
however, β2-adrenoceptors have been shown to play a critical role (Yalcin et al. 2009). 
 
Antispasmodics 
First-line treatment of spasms is with baclofen. Baclofen is a GABA agonist, designed as a 
lipophilic derivative of GABA to enhance its transport across the blood–brain barrier. 
Selectively binding at pre-synaptic GABAB receptors, it inhibits both mono- and polysynaptic 
activation of motor neurons in the spinal cord (Rang et al. 2007). Adverse reactions include 
drowsiness, motor incoordination and nausea. Severe spasticity is sometimes treated with a 
programmable intrathecal baclofen pump. 
Botulinum toxin is a neurotoxin causing long lasting paralysis and is used to treat spasms in 
specific muscles. Botulinum toxin exhibits its effect by inhibiting acetylcholine release. 
Systemic adverse reactions are avoided, because it is injected peripherally.  
Recently the cannabinoid oromucosal mouth spray “Sativex” has been approved for use in 
MS patients with unsatisfactory effect from first-line antispasmodic treatment (Hortemo 
2012). It is, however classified as an analgesic and antipyretic drug, according to the ATC 
register (whocc.no). It has proven efficacious for treatment of spasms in randomized 
placebo-controlled trials (Oreja-Guevara 2012). Sativex has also been studied with regards to 
its effect on central pain in MS patients, the effect was significant, however the adverse 
reactions should still be investigated further (Chaparro et al. 2012, Langford et al. 2012).  
Clonazepam can also be used to treat spasms. It is often administered in the evening, due to 
its sedative effect. 
 
Antiepileptic drugs 
There are three main mechanisms of action for antiepileptic drugs, enhancement of 
GABAergic action, inhibition of glutamatergic excitation and inhibition of voltage-gated 
sodium and calcium channels. The first known class of antiepileptic drugs, benzodiazepines, 
act by allosterically modulating the GABAA receptor, thus enhancing its time spent in the 
active confirmation and thereby increasing Cl
-
 conductance. 
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Carbamazepine inhibits voltage-gated sodium channel function with a higher affinity for the 
inactivated state of the channel. Since there are more inactivated channels in a neuron firing 
repetitively, these drugs preferentially block the excitation of neurons that are firing 
excessively (Perucca 2005). A major reason for discontinuation of carbamazepine treatment 
both in epilepsy and MS patients is skin rash (Shirzadi et al. 2012). 
Gabapentin was designed to resemble GABA, but also, unlike GABA, cross the 
blood−brain barrier. The idea was for gabapentin to bind GABA receptors and thereby mimic 
its effects. Although gabapentin did reduce seizures in animal models, it did not bind to 
GABA receptors. Instead, it was found to block L-type calcium channels by binding 
specifically to the α2δ1-subunit (Sills 2006). The L-type calcium channel is voltage-gated and 
mediates long lasting potentials. Gabapentin has been shown to affect several physiological 
targets, it seems however, that the inhibition of the voltage-gated calcium channel is 
predominantly responsible for its pharmacological actions (Sills 2006).  
In addition to its anticonvulsant effect, gabapentin has also shown efficacy in treatment of 
neuropathic pain. Several potential mechanisms for gabapentin’s effect on neuropathic pain 
have been proposed and one does not exclude the other. Gabapentin’s antinociceptive action 
may result from direct inhibition of the afferent signal to the spinal cord, and also it has been 
shown to reduce the enhanced spinal glutamate release following noxious stimuli in 
neuropathic rats (Johannessen Landmark 2008). It is believed that binding to the α2δ1-subunit 
of calcium channels is responsible for gabapentin and pregabalin’s pain-relieving effect 
(Johannessen Landmark 2008). Pregabalin is a more potent follow-up of gabapentin with 
similar pharmacological actions. These two drugs are predominantly utilised in treatment of 
neuropathic pain (Johannessen Landmark et al. 2009). 
 
Benzodiazepines 
The first benzodiazepine, chlordiazepoxide, was synthesised in 1961. Today, benzodiazepines 
are used for their anxiolytic, hypnotic and anticonvulsant effects. Benzodiazepines act 
selectively on GABAA receptors, allosterically increasing the affinity of GABA for the 
receptor. The unwanted effects vary with indication and between specific substances; their 
joint flaw in long-term treatment is the development of dependence and tolerance. The newer 
generation of benzodiazepines used to treat insomnia, termed Z-hypnotics (e.g. zopiclone, 
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zolpidem), have a shorter half-life (1–6 hours) and cause less of a hangover than their 
predecessors (Mellingsaeter et al. 2006). 
 
Opioids 
The well-known powder, opium, has been used for thousands of years, both medicinally and 
socially. Opium consists of a number of alkaloids related to morphine. Opiates are structures 
resembling morphine, whereas opioids are all substances producing morphine-like effects that 
can be blocked by an antagonist (e.g. naloxone). 
Opioids are the most effective analgesics available, unfortunately inseparable from tolerance 
and dependence issues (Plante and VanItallie 2010). There are mainly three different opioid 
receptors, µ, δ and κ. The endogenous ligands are termed enkephalins (peptides). Different 
substances have different binding profiles with regard to the receptor subtypes. The binding 
profile of any given substance determines its in vivo effects (Plante and VanItallie 2010). The 
µ-receptor is responsible for most opioid effects, including physical dependence. 
Codeine is a pro-drug for morphine and other active metabolites. Codeine is more reliably 
absorbed when administered orally than morphine. Codeine only has 20 % of the analgesic 
effect of morphine and it does not increase much at higher doses. The risk of abuse and 
dependency is little and therefore it is sold without prescription in some countries (Rang et al. 
2007). About 10 % of the population lacks the enzyme converting codeine to morphine and 
will therefore, not experience any effects. 
 
1.3.4 Drug interactions 
The many symptomatic and fewer disease-modifying treatment options available, often result 
in polypharmaceutic treatment of the individual patient. Therefore, awareness of potential 
interactions is of major importance. Age and gender may have an impact on the likelihood of 
interaction development (Gidal et al. 2009). The clinical consequence of a specific drug 
interaction may be anything from irrelevant to fatal. Different aspects of the pharmacological 
treatment may be affected, such as the drug efficacy or the adverse reaction profile.  
Drug interactions are either pharmacokinetic or pharmacodynamic. Pharmacokinetic 
interactions affect drug absorption, distribution, metabolism and/or excretion. They are often 
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the result of limited capacity of endogenous enzymes in intestine, liver or kidneys. 
Pharmacokinetic interactions alter the serum drug concentration (Johannessen Landmark and 
Patsalos 2010). Pharmacodynamic interactions may arise when multiple drugs affect the same 
target protein, but they do not affect the serum drug concentration. One example could be a 
synergistic effect, achieved by using two different blood-pressure lowering drugs to sustain a 
lower blood-pressure than what could be achieved with a higher dosage of a single drug. 
Several hundred pharmacokinetic interactions involving AEDs have been reported, but only a 
handful pharmacodynamic interactions (Johannessen Landmark and Patsalos 2010). 
 
1.4 Life with MS 
Multiple sclerosis is the most common neurologically debilitating disease among young 
adults. The many disorders associated with MS combined with the broad spectre of MS 
symptoms, including cognitive, motoric and sensory symptoms, highlight the need for a wide 
range of therapeutic approaches by many different professionals to treat the individual patient 
optimally. Therefore, the staff at MSSH includes eight different professions (e.g. neurologist, 
neuropsychologist, general psychologist, physiotherapist, occupational therapist, nurses, 
social workers and a nutritionist) (mssenteret.no 2013). 
The median time from disease onset to the patient reaches EDSS level 4.0 (limited walking 
distance) is 8–10 years and the median time to reach EDSS level 7.0 (need wheelchair) is 
30 years (Beiske 2009). Health-related quality of life is lower in MS, than in other chronic 
disorders. MS patients experiencing pain symptoms have an overall lower quality of life than 
those without pain (Svendsen et al. 2005). Sustaining employment after the MS diagnosis and 
a higher level of education is associated with better quality of life (Patti et al. 2007). 
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2. Material and methods 
2.1 Study material 
The study was performed at the Centre for MS-rehabilitation Hakadal, Norway. The present 
study is a retrospective study of pharmacological treatment of patients admitted to the 
MS centre, based on data from the medical records. 
All medical records at MSSH are stored in a local administrative database, accessible through 
designated software named Extensor. To access these records I was given administrative 
privileges in Extensor and had to sign a confidentiality agreement. All records from the period 
01.01.2009 to 31.12.2011 were reviewed, representing a total of 869 unique patients. 
Information on patients treated with at least one AED or amitriptyline (a tricyclic 
antidepressant) was collected. This was done to investigate the suspected polypharmacy 
issues and potential for pharmacokinetic and pharmacodynamic interactions following use of 
AEDs. Amitriptyline was added as an inclusion criteria, as it is used in treatment of 
neuropathic pain and could cause pharmacodynamic interactions, in line with AEDs. 
 
2.2 Inclusion criteria 
The inclusion criteria were the MS diagnosis and the use of at least one antiepileptic drug or 
amitriptyline. Antiepileptic agents were defined as any drug with ATC-code N03Axxx, 
according to the Norwegian ATC-register (Anatomical Therapeutic Chemical classification). 
All patients registered in the Extensor database are diagnosed with MS. Some patients had 
more than one stay at the centre during the inclusion period. In those cases the most recent 
stay was chosen and previous stays were disregarded. 
If the medical record included an EDSS score, the EDSS score together with the patient’s 
gender and age was collected, even if the patient failed to meet the inclusion criteria. This was 
done to provide a means to characterise the total patient population with an EDSS profile and 
thus evaluate how well it represents the national MS population. An EDSS profile of the study 
population describes a distribution of functioning scores among the patients. Comparing the 
study-population’s EDSS profile with a regional distribution will show whether the study 
results may apply to other MS populations as well. 
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For the inclusion year 2009, all patients receiving disease-modifying treatment were included. 
This was done to investigate potential interactions, characterise the study population and 
possibly to contribute in the ongoing debate of financing disease-modifying treatment of MS 
patients. 
 
2.3 Exclusion criteria 
Exclusion criteria were lack of treatment with either an AED or amitriptyline. Patients 
without stays at the MS centre during the inclusion period (01.01.2009 to 31.12.2011) were 
also excluded. Medical records with insufficient data regarding gender or age were 
disregarded. 
 
2.4 Registration and storage of patient data 
For every included patient, the following was registered in the spread sheet: 
 Age 
 Gender 
 EDSS score 
 Epilepsy diagnosis 
 All current medication including dosages 
 Extensor patient id number  
The Extensor patient id number is a number assigned by Extensor for every new patient 
stored in the database. Registering this number with every patient in the spread sheet allows 
tracking for quality assurance aspects and improves patient data safety compared to assigning 
study-specific patient id numbers and creating a key spread sheet. In this way, only those with 
access to the original medical records in Extensor are able to identify patient identities from 
the study’s spread sheet. 
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2.5 Study scope 
Some drugs were considered especially relevant for potential interactions (mostly 
pharmacodynamic) with AEDs and amitriptyline. To study the use of those drugs in more 
detail, they were divided into subgroups based on their mechanism of action. Potential groups 
which would have contained less than five patients were disregarded. Data belonging to each 
of the following groups was studied in separate spread sheets: 
Table 3. Drug subgroups 
 
 
 
 
 
 
*All drugs in Norway are divided into prescription classes depending on their characteristics. 
Classes “A” and “B” have a potential for abuse and there are special requirements following 
those prescriptions. With a few important exceptions, opioids are in class “A”, which is the 
class associated with the greatest risk of abuse. The dividing of opioids in classes “A” and 
“B” seems appropriate, due to the important differences between the opioid substances and 
henceforth all matters regarding opioids in this thesis will reflect upon this classification. 
 
2.6 Calculations and statistical analysis 
The entire studied population included 869 unique patients. However, since some patients 
failed to meet any of the inclusion criteria, the gender and age of only 566 patients was 
recorded. EDSS scores were available for 343 patients. 
The collected data was filtered and processed using Open Office calc (version 3.3.0). The 
statistical program Minitab (version 16.1.0) was used for performing statistical tests and 
creating figures. Microsoft Excel 2010 (version 14.0.) was also used to create figures and 
tables. P-values ≤ 0.05 were considered as statistically significant. The following statistical 
Group name Examples 
Alpha-2 blockers Mianserin, mirtazapine 
Antispasmodics Baclofen 
Benzodiazepines Z-hypnotics: 
Zolpidem, zopiclone 
Other: 
Diazepam 
Opioids* A: Oxycodone, buprenorphine B: Tramadol, codeine 
SSRIs and SNRIs Escitalopram, venlafaxine etc.  
Central stimulants Modafinil 
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tests were applied: Fischer’s t-test for binomial distributions, Mann-Whitney for comparing 
non-parametric data (EDSS scores) and student’s t-test when comparing normally distributed 
data (for example drug dosages). 
 
2.7 Ethical considerations 
The study was approved by the local ethics committee at MSSH. All data were handled 
anonymously and retrospectively. The study results will benefit the study population. Since 
the nature of this study is quality assurance of treatment with AEDs at MSSH, it was 
considered no need for patient informed consent according to Norwegian law 
(helseforskningsloven). Otherwise, performing such studies would not be possible. 
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3. Results 
3.1 Study population 
The included study population and subpopulations from MSSH are schematised in figure 4. 
 
 
Figure 4. General study population and subpopulations 
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3.2 Demographics 
3.2.1 Demographic characteristics of the general MSSH population 
The mean age and EDSS score of all available patient data is displayed in table 4. The mean 
age was 54 for both genders and their average EDSS scores were consistent. As expected in 
any unbiased MS population, there were about 70 % women. 
 
Table 4. MSSH demographic 
 
N Age: mean (range) EDSS: mean (range; N*) 
Registered population 566 54.4 (20–77) 4.8 (1–8; 343*)  
Women 388 54.3 (20–74) 4.7 (1–8; 237*) 
Men 178 54.7 (25–77) 4.9 (2–8; 106*) 
*Gender and age is included in all medical records, unfortunately some medical records lacked an EDSS score, 
the number of available EDSS scores in each group is denoted in the last column. 
 
The age distribution of the registered population is displayed in figure 5. There was a large 
increase in frequency of men from the 30–39 age group to the 40–49 age group. There is also 
a large increase in the frequency of women in the age group 50–59 compared to the 40–49 age 
group.  
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Figure 5. MSSH age distribution 
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The EDSS score distribution of all available EDSS scores (n=343) from the entire population 
(n=869), is shown in figure 6.  
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Figure 6. EDSS distribution 
 
3.2.2 Patients using AEDs or TCAs 
There were 23 patients with epilepsy in addition to MS, representing 2.6 % of the general 
MSSH population and 7.7 % of the AED/TCA population. The focus of this study further on 
is, however, the use of AEDs and TCAs in the treatment of pain. 
The mean EDSS score of the AED/TCA population is 4.82 (n=140), whereas the population 
of non-AED/TCA users has an average EDSS score of 4.72 (n=208). The mean age of the 
AED/TCA users is 55.2 (n=297) and for the non-users it is 53.4 (n=260). An overview of the 
AED/TCA demographic and corresponding EDSS scores is given in table 5.  
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Table 5. AED/TCA demographic 
Age N Avg EDSS (N) [Women] 
20–29 3 3.5 (2) 67 % 
30–39 17 4.2 (3) 82 % 
40–49 52 4.7 (30) 67 % 
50–59 119 4.7 (65) 70 % 
60–69 95 5.6 (36) 71 % 
70–79 11 4.25 (4) 73 % 
 
The AED/TCA subpopulation included 106 (35.7 %) patients who were 60 years or older. 
 
3.3 Use of AEDs and TCAs 
We found that 34.2 % (n=297) of the patients in the period 2009–2011 used at least one AED 
and/or TCA. Table 6 shows the five most commonly prescribed drugs from this group. AEDs 
were prescribed most frequently for the treatment of pain/spasms, but there were also a few 
patients who used AEDs for epilepsy, bipolar disorder and migraine (Table 2 and 3). There 
were 20.5 % (n=178) of the patients who used at least two out of these five drugs. AEDs were 
prescribed to 25.7 % (n=223) of the patients for treatment of pain. The AEDs which were less 
frequently prescribed than carbamazepine are rarely used in pain treatment. For patients with 
MS, vice versa is also true; the most commonly prescribed AEDs/TCAs are almost 
exclusively prescribed for the treatment of pain. Of the AEDs described gabapentin and 
pregabalin are categorised as having very low propensity for pharmacokinetic interactions, 
clonazepam as moderate, while carbamazepine has a considerable potential for interactions. 
The less commonly prescribed AEDs are listed in table 7. There was considerable dosage 
variation, for example the maximum dosage of pregabalin was 18 times larger than the 
minimum dosage described. Gabapentin also showed large dosage variation, where the 
maximum dosage prescribed was 12 times larger than the minimum. 
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Table 6. Most commonly used AEDs and TCA 2009-2011 
Drug Drug 
class 
N Average 
dosage (mg) 
Range 
(mg) 
Bipolar 
diagnosis 
Epilepsy 
diagnosis 
Pain or 
spasms*  
Propensity 
to interact 
Gabapentin AED 109 1517 300–
3600 
                    1  Very low 
   12.5 %          
Clonazepam AED 69 1 0.25–3   1 68 Moderate 
   7.9 %          
Pregabalin AED 66 341 50–900   1 65 Very low 
   7.6 %          
Carbamazepine AED 21 473 200–800 1 3 17 Substantial 
   2.4 %          
Amitriptyline TCA 84 30 10–75   1  83 - 
   9.7 %          
*Pain/spasms was assumed when no other indication was reported. Propensities of AEDs to interact are based on 
review by Landmark and Patsalos 2010. TCA (tricyclic antidepressant); AED (antiepileptic drug) 
 
 
Table 7. Less commonly used AEDs 2009-2011 
Drug N Average 
dosage (mg) 
Range 
(mg) 
Bipolar 
disorder 
Epilepsy 
diagnosis 
Migraine Mood 
disorder 
Pain* Propensity 
to interact 
Lamotrigine 15 195 75–800  7  3 5 Substantial 
Valproate 8 1029 600–1500 1 3 1  3 Substantial 
Levetiracetam 3 1000 500–1500  3    Very low 
Oxcarbazepine 3 1080 600–1440  1   2 Moderate 
Phenytoin 2 150 100–200  2    Substantial 
Topiramate 1 100 NA  1    Substantial 
Phenobarbital 1 45 NA  1    Substantial 
*Pain was assumed when no other indication was reported. Propensities to interact are based on review by 
Landmark and Patsalos 2010. TCA (tricyclic antidepressant); AED (antiepileptic drug) 
 
Of the less commonly used AEDs all are considered as substantially likely to cause 
pharmacokinetic interactions, except for oxcarbazepine and levetiracetam, which propensities 
are categorised as moderate and very low, respectively. 
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3.3.1 Dosage variations of pregabalin versus gabapentin 
To compare the dosage variability of gabapentin versus pregabalin, the dosages were 
normalised by dividing each value by the mean. Figure 7 shows a boxplot of the normalised 
dosages. The interquartile range (IQR) is about the same, but clearly the upper quartile of the 
gabapentin dosages are wider spread from the mean than the pregabalin dosages. The 
variances for the whole samples are not significantly different from one another. 
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Figure 7. Dosage variation of PGB versus GBP 
PGB (pregabalin); GBP (gabapentin) 
 
3.3.2 Drug combinations with pregabalin and gabapentin 
Different drug combinations with pregabalin or gabapentin were studied. We found that in the 
AED/TCA population, it is 77 % more likely that a patient using a Z-hypnotic also uses 
pregabalin, than that a patient not using a Z-hypnotic is using pregabalin. Fischer’s exact test 
(for difference=0) was applied to test for significance in difference of the binomial 
distribution, the hypothesis was disproved with a p-value of 0.02. The same procedure was 
followed with gabapentin in combination with the Z-hypnotics, but the binomial distributions 
did not differ significantly.  
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Of the patients receiving oxycodone (n=9) in the AED/TCA population at MSSH, four used 
pregabalin, three gabapentin, one amitriptyline and one lamotrigine.  
There was no correlation between use of opioids and pregabalin and/or gabapentin.   
 
3.3.3 The development of use of AEDs and TCAs from 2009 to 2011 
The development of the most commonly used AEDs/TCAs from 2009 to 2011, is displayed in 
figure 8. The use of gabapentin doubles from 2010 to 2011. Fischer’s test was applied to test 
for significance in difference between the distribution of gabapentin users and non-users, for 
2010 versus 2011. The test proved that the distribution is significantly different in 2010 as 
compared to 2011 (p=0.02).  
 
 
Figure 8. AEDs and TCA used for treatment of neuropathic pain 2009-2011 
TCA (tricyclic antidepressant); AED (antiepileptic drug) 
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3.4 Aspects of polytherapy 
3.4.1 Drug count distribution 
The average patient in the AED/TCA subpopulation uses a total of 5.36 (1–19) different 
prescription drugs. The drug count distribution is shown in figure 9. In the AED/TCA 
subpopulation 57 % of the patients used 5 or more drugs and 6.7 % of patients were using 10 
drugs or more.  
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Figure 9. EDSS distribution 
 
3.4.2 Most commonly used prescription drugs 
On average men used 4.7 drugs each, while women used 5.6. The only drug prescribed 
significantly different to men and women was mirtazapine, with some exceptions such as 
hormones. Mirtazapine was used by four men, but only by one woman; keeping in mind that 
the population includes about twice as many women as men, this is a substantial difference 
(Fischer’s test, p=0.02). It is worth mentioning that natalizumab showed a tendency towards 
being more commonly prescribed in women than men, although non-significant (p=0.06). 
The 15 most commonly used prescription-drugs are listed in table 8 with corresponding 
rankings for women and men respectively. 
28 
 
Table 8. Top 15 prescription drugs 
 Drug N (297) Indication Ranking for 
women 
Ranking 
for men 
1. Gabapentin 36.7 % Neuropathic pain 1. 1. 
2. Baclofen 27.6 % Spasms 2. 2. 
3. Amitriptyline 28.3 % Neuropathic pain 3. 3. 
4. Clonazepam 23.6 % Spasms/pain, insomnia 5. 4. 
5. Pregabalin 22.2 % Neuropathic pain 4. 5. 
6. Tolterodine 15.2 % Bladder dysfunction 6. 7. 
7. Methenamine Hippurate 13.1 % Urinary antiseptic 7. 8. 
7. Solifenacin 13.1 % Bladder dysfunction 9. 6. 
7. Zopiclone 13.1 % Insomnia 11. 10. 
10. Interferon-beta 11.8 % Relapsing-remitting MS 8. 11. 
11. Levothyroxine 10.8 % Low metabolism 9. 18. 
11. Simvastatin 10.8 % High cholesterol 10. 14. 
12. Codein + acetaminophen 9.4 % Pain 16. 10. 
13. Acetylsalisylic acid 9.1 % Anticoagulant 17. 9. 
14. Glatiramer Acetate 8.8 % Relapsing–remitting MS 13. 14. 
15. Natalizumab 8.1 % Relapsing–remitting MS 12. 27. 
 
 
3.4.3 Comedication affecting the CNS 
As described in section “2.5 Study scope”, some drug classes were of special interest and 
their prescription is summarised in table 9. Half of the patients use at least one 
benzodiazepine (excluding clonazepam, which was defined as an AED), an opioid or baclofen 
in addition to their AED/TCA treatment. The combined use of A and B opioids includes 62 
unique patients, representing 20.9 % of the AED/TCA subpopulation. The patients using 
opioids in the AED/TCA subpopulation had a significantly higher median EDSS score than 
the other AED/TCA patients (Mann-Whitney test: EDSSopioid=5.5; n=33 and 
EDSSnon-opioid=4.5; n=103; p=0.01; W=2757.5). There was an 8–9 fold dosage variation of 
baclofen, tramadol and escitalopram (table 9). 
  
29 
 
Table 9. Comedication affecting the CNS 
 
N (%) N 
Average dosage 
(mg) 
Range (mg) Indication 
Alpha-2 blockers 2.0 % 6 
  
Depression 
Mianserin 
 
1 30 (30) 
 
Mirtazapine 
 
5 27 (15–30) 
 
Antispasmodic 27.5 % 82 
  
Spasm 
Baclofen 
 
82 32.8 (10–90) 
 
Opioids A* 7.4 % 22 
  
Pain 
Oxycodone 
 
9 24.5 (10–54) 
 
Buprenorphine 
 
4 NA 
  
Other 
 
14 
   
Opioids B* 14.4 % 43 
  
Pain 
Codeine 
 
30 NA 
  
Tramadol 
 
15 252.3 (50–400) 
 
SSRI/SNRI 17.8 % 53 
  
Depression 
Escitalopram  18 14.7 (5–40)  
Citalopram 
 
17 23.5 (10–40) 
 
Venlafaxine 
 
7 128.6 (75–225) 
 
Other  11    
Benzodiazepines** 18.9 % 56 
   
Diazepam 
 
12 8.5 (4–15) Anxiety 
Zopiclone  38 6.7 (2.5–7.5) Insomnia 
Zolpidem 
 
9 10.6 (10–15) Insomnia 
Central stimulants 
     
Modafinil 
 
5 160 (100–200) 
Narcolepsy 
Fatigue 
*describing Norwegian prescription classes; **Benzodiazepines excluding clonazepam 
 
 
  
30 
 
3.5 Disease-modifying treatment 
An overview of the disease-modifying treatment of patients in the period 2009–2011 is given 
in table 10. In 2009, patients receiving beta-interferon and patients not receiving 
beta-interferon were treated equally often with AEDs/TCA (30.8 % and 33.5 %, respectively).  
Table 10. Disease-modifying treatment 2009-2011 
 2009 2010 2011 
Population General AED/TCA AED/TCA 
N 236 97 126 
Disease-modifying treatment 31.8 % 31.0 % 31.0 % 
1
st   
line-treatment  
(beta-interferon, glatiramer acetate) 
82.7 % 66.7 % 56.4 % 
2
nd
 line-treatment 
(natalizumab, fingolimod) 
14.7 % 30.0 % 35.9 % 
3
rd 
 line-treatment 
(mitoxantrone) 
2.7 % 3.3 % 7.7 % 
 
The use of first-line treatment was predominant in all inclusion years. Although the 
proportion of MSSH patients treated with disease-modifying drugs remained constant, use of 
second- and third-line treatment increased throughout the inclusion years. The mean 
amitriptyline dosage in the interferon-beta population was 36.9 (n=13), and in the 
non-interferon-beta population it was 29.2 (n=63). The 2-sample t-test showed that the 
difference in mean amitriptyline dosages was not significant (p=0.25). 
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4. Discussion 
4.1 Discussion of results 
This study adds to the research on pharmacological treatment of pain in MS, while it focuses 
on the rationale of the treatment with AEDs and TCAs in light of polypharmacy issues. 
Relating pharmacological treatment to patients’ degree of disability with a special focus on 
pain therapy is a new approach to apply current knowledge of evidence-based medicine for 
the benefit of MS patients.  
There is a wide span of symptomatic treatment options applied to improve the quality of life 
of MS patients. Pain is a very common and disabling symptom. One in every three patients in 
the general MSSH population is treated pharmacologically to relieve pain, including patients 
of all ages, genders and degrees of disability. In a study of pain in 142 MS patients, 
65 % reported that they experienced pain (Beiske et al. 2004). It was also found that the pain 
was independent of demographic variables. However, only one third of the patients were 
treated for their pain. It is unlikely that the prevalence of pain has changed in the last ten 
years, so it seems that more patients are receiving treatment. 
 
4.1.1 Demographics 
General MSSH population 
The mean age of the population was 55.4 years. A comparable statistic from another 
cross-sectional Norwegian MS population has not been found, since it is more common to 
report the average age at disease onset. Age at disease onset was not registered in this study 
since it is rarely in found in medical records. By combining the reported age at disease onset 
and average disease duration, the average age of an MS population in eastern Norway was 
calculated to be 49.8 years (n=140) (Beiske et al. 2008).  
The frequency of men in the general MSSH population increases substantially from the 30–39 
age group to the 40–49 age group, this is likely explained by the fact that PPMS is more 
common in men, because the mean age of PPMS onset is about 40 years (Myhr et al. 2001). 
This also explains why the proportion of women is higher in the age group 30-39. The 
increase in frequency of women in the age group 50–59 compared to the 40–49 group, may be 
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explained by the fact that they have older children. A stay at MSSH is usually four weeks 
long and this may be considered too long by women with younger children at home. 
The EDSS distribution characterises the general MSSH population with regards to function 
level and thereby provides a means to compare the population with other populations as well. 
We can tell that a broad spectre of patients have stayed at MSSH in the inclusion years. The 
peaks at score 4.0 and 6.5 are typical for cross-sectional studies of MS populations. Myhr et 
al. (2001) described the same peaks (2.0–3.5; 6.0–8.0; n=220) in his study of MS patients in 
Hordaland county and explained that they are consequences of the disease course; at these 
function levels the disability progresses slower. The mean EDSS score of the Hordaland 
population was 4.5 ± 0.2 (s.e.), the MSSH population’s mean EDSS score was 4.75 ± 0.1. The 
MSSH population seems to be representative of the geographically determined Hordaland 
population with regards to degree and distribution of disability. This observation suggests, 
that we may allow for our results to be projected on to other MS populations. Comparing the 
disability distributions of the two populations is especially important to this study, since it 
provides a means for quality assurance by controlling eventual inclusion bias. For example, 
the main intake criteria at MSSH (potential for rehabilitation) could be a cause of such. 
 
Prevalence of epilepsy 
The MSSH population had a prevalence of epilepsy of 2.6 %. This is two to three times the 
prevalence of epilepsy in the general population and is in accordance with previous studies 
(Koch et al. 2008). Etemadifar et al. studied the demographics of their EP/MS (epileptic MS) 
population versus their non-EP/MS population looking for a possible link explaining the 
increased epilepsy prevalence. They found that the frequency of EOMS in the EP/MS 
population was twice that of the EOMS frequency in the non-EP/MS population (12.3 and 
5.9 %, respectively). Neuroimaging studies have related cortical and subcortical lesions to 
ictal behaviour and this is the most commonly supported hypotheses for explaining the 
increased epileptic seizure prevalence (Truyen et al. 1996).  
The distribution of EDSS (bi-modal), gender, age and epilepsy prevalence all indicate that a 
representative MS population has been included in this study. 
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AED/TCA subpopulation 
To elucidate the potential polypharmacy issues related to the use of AEDs and TCAs it is 
appropriate characterise the population using them. Does this population differ from the 
population of MS patients not using AEDs or TCAs? 
The epilepsy prevalence in the AED/TCA subpopulation is higher than in the general MSSH 
population (7.7 and 2.6 %, respectively); still more than 90 % of the population are using the 
drugs for other indications than epilepsy. We have shown that the AEDs and TCAs are 
primarily used for treating pain. There is no difference in age, gender or degree of disability 
when comparing the general MSSH population and the AED/TCA subpopulation. 
 
4.1.2 Use of AEDs and TCAs 
Antiepileptic drugs 
Gabapentin and pregabalin were the most frequently prescribed drugs for continuous 
treatment of pain in the AED/TCA subpopulation. Although more patients were using 
clonazepam than pregabalin, many of the patients using clonazepam are using it sporadically. 
In a national study of prescriptions in Norway, throughout 2007, pregabalin was the most 
prescribed AED and gabapentin the second most prescribed AED for treatment of neuropathic 
pain (Johannessen Landmark et al. 2009). 
From 2010 to 2011 the proportion of patients using gabapentin at MSSH doubled. The 
explanation for this dramatic difference may be an indirect effect coming from a change of the 
refund policy as of May 1
st
, 2009, by Norwegian health authorities on pregabalin 
prescriptions (HELFO 2009). The new regulation demanded that all patients had to try 
gabapentin before they could be given pregabalin, most likely because pregabalin is more 
expensive. Prescriptions are typically valid for one year, delaying the effect of this regulatory 
change. It is not unlikely that gabapentin since then has overtaken pregabalin as the most 
common AED for neuropathic pain nationally. In MS, pregabalin and gabapentin can also be 
used to treat spasms in addition to baclofen in cases difficult to treat (Beiske 2009). 
A recent Cochrane review on gabapentin for chronic neuropathic pain and fibromyalgia 
concluded that adverse effects of gabapentin are common, but mild (Moore et al. 2011). Only 
one in every ten patients stopped treatment due to adverse reactions. The Cochrane review did 
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not focus on central pain and therefore the authors conclusions on efficacy do not apply to MS 
related neuropathic pain. The European Federation of Neurological Societies (EFNS) classify 
pregabalin as level A and gabapentin as level A/B with regards to efficacy in central pain and 
both are recommended as first-line treatment (Attal et al. 2010). 
Even though the effects of gabapentin and pregabalin are similar in most patients, a reduced 
uptake of gabapentin has been shown in as many as 40 % of patients (Gidal et al. 2000). 
Those 40 % may fail treatment with gabapentin or require higher dosages than other patients. 
Since pregabalin does not have the same issue, we suspected that we might find a larger 
variation in the dosages of gabapentin as compared to pregabalin. The gabapentin dosage 
distribution did have a right-sided tail, which could be caused by a reduced gastrointestinal 
absorption in some patients.  
 
Tricyclic antidepressants 
Less than five patients were treated for depression with a TCA, therefore this indication for 
TCAs will be discussed no further. The only TCA used for treatment of pain was 
amitriptyline. The EFNS guidelines recommend amitriptyline as first-line treatment for 
central pain (Attal et al. 2010). In addition to the regular tablets, there is also a depot 
formulation available. Most medical records included the regular tablets, but some did specify 
that the depot formulation was being used. Either the prescribing doctors should be more 
precise when writing medical records or many patients may benefit from changing to the 
depot formulation. Especially when there is a potential for pharmacodynamic interactions, a 
depot formulation which reduces Cmax can reduce the magnitude of peak concentration related 
adverse reactions. The involvement of β2-adrenoceptors in TCA’s mechanism of action for 
relieving neuropathic pain suggests an incompatibility with beta-blockers that affect these 
receptors (Yalcin et al. 2009). This may be an important notion considering the number of 
patients treated with amitriptyline and switching to a different antihypertensive should be 
simple. 
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4.1.3 Comedication affecting the CNS 
SSRIs and SNRIs 
SSRIs/SNRIs were used by 18 % of the AED/TCA subpopulation. These drugs are mainly 
used to treat depressions, which are twice as common among MS patients as in the general 
population (Beiske et al. 2008). The study of 140 Norwegian MS patients also showed that 
31.4 % had symptoms of depression and that only 15.9 % of them were receiving treatment.  
There were surprisingly large variations in the dosages of citalopram (10–40 mg) and 
escitalopram (5–40 mg) in the AED/TCA subpopulation. Dosages of more than 20 mg 
escitalopram per day have not been tested with regards to safety and should in general not be 
given (SmPC-escitalopram 2013). Although SSRI/SNRIs are useful in treatment of peripheral 
neuropathic pain since they are generally better tolerated than TCAs, they have never been 
proven efficacious for treatment of central neuropathic pain (Attal et al. 2010). The dosage 
variation may still be a result of attempting treatment of pain or depression.  
 
Opioids 
Opioids were used by 21 % of the AED/TCA subpopulation. Opioids are considered the last 
resort for long-term pain management due to the likely development of tolerability and risk of 
dependence. This is confirmed by our finding that the patients receiving opioids in addition to 
an AED or TCA have significantly higher EDSS scores than AED/TCA patients who are not 
receiving opioids. Dependence issues are less commonly associated with “B group” opioids 
(tramadol and codeine) than “A group” opioids (oxycodone, buprenorphine etc.). Large 
dosage variations were seen with tramadol treatment (50–400 mg). Adjusting dosages to the 
minimum which still provides satisfactory pain-relief is important when opioids are applied in 
long-term treatment. This will reduce common adverse effects such as constipation and also 
reduce development of tolerability. Tramadol inhibits noradrenaline reuptake in addition to 
binding the µ-opioid receptor. Therefore it has a better dose-effect ratio compared to 
morphine for treatment of neuropathic pain than it has compared to morphine for treatment of 
nociceptive pain (Smith 2012).  
Controlled-release oxycodone and pregabalin in combination for treatment of non-cancer pain 
proved efficacious and was recommended after a one-year long study of more than 
1000 patients (Gatti et al. 2011). A recent Cochrane review concluded that gabapentin in 
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combination with an opioid provides better pain-relief than gabapentin alone in both 
peripheral and central neuropathic pain, but adverse reactions were also more common 
(Chaparro et al. 2012). 
 
Benzodiazepines 
Clonazepam is particularly interesting when it comes to treatment of MS patients. As a 
sedative or an antiepileptic it is not considered first- or second-line. However, clonazepam’s 
sedative, antispasmodic and pain relieving effects combined make it useful for MS patients in 
the evening. 
There have been reports of use misuse of pregabalin and gabapentin (Caster et al. 2011, 
Prescrire 2012). Therefore we wanted to see if these drugs were more commonly used in 
combination with other drugs with a sedative effect and a potential for misuse. Our finding 
that it is much more likely for a patient using a Z-hypnotic to be using pregabalin than any 
other patient in the AED/TCA population adds to this. Furthermore, it highlights the possible 
presence of a pharmacodynamic interaction.  
 
4.1.4 Disease-modifying treatment 
With new and increasingly expensive disease-modifying drugs becoming available during the 
last decade, there has been an ongoing debate on their funding. There are those who believe 
that the availability of disease-modifying treatment is unequal throughout the country, which 
is unacceptable for the social democracy. “The economic model for funding the costs of these 
drugs forces hospitals to choose the cheapest available option”, according to health economist 
Bjørn Svendsen (Nordahl 2012). Second-line treatment options (fingolimod and natalizumab) 
are more expensive, but have proven to reduce more attacks. Nationally 43 % of patients are 
treated with first-line drugs and 13 % with second-line drugs in 2011 (Link-Medical 2012). 
In the 2011 AED/TCA population at MSSH 17 % received first-line treatment and 11 % 
second-line treatment. Nationwide, 56 % of patients were receiving disease-modifying 
treatment, while this only was true for 31 % of the patients at MSSH. The large difference 
may come from a difference in proportion of RRMS patients, but this is difficult to determine 
as we don’t have these data available. The MSSH population may be older than the national 
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MS population, providing a shift from RRMS to SPMS patients and thus lowering the 
proportion treated with disease-modifying drugs.  
The average dosages of the comedication used by the population of interferon-beta users was 
studied, because it has been shown that interferon-alpha inhibits CYP enzyme activity 
(Christensen and Hermann 2012). Amitriptyline was the only drug metabolized by CYP 
enzymes, for which we possibly had a large enough sample size to compare dosages of 
interferon and non-interferon receiving patients (Olesen and Linnet 1997). In contrast to what 
was expected, the amitriptyline dosages of the interferon-beta users were actually 
insignificantly higher than the corresponding dosages of the non-interferon-beta users. 
 
4.1.5 Polytherapy considerations 
Pharmacokinetic and -dynamic interactions 
Even though the patients at MSSH frequently used AEDs in combination with other drugs, 
they rarely used the AEDs most susceptible to drug related problems. Instead they used the 
newer generation AEDs, gabapentin and pregabalin. These drugs are not associated with 
pharmacokinetic interactions like the AEDs of the previous generation (Johannessen 
Landmark and Patsalos 2010). Patients with epilepsy and MS require more attention since 
they use a wider range of AEDs. 
A recent Cochrane review on combination treatment of neuropathic pain reported that the 
number of drop-outs due to adverse reactions often was higher in combination therapy and 
that this limits its application. One fifth of the general MSSH population used at least two of 
the included AEDs/TCAs and more than half of the AED/TCA subpopulation used an opioid, 
a benzodiazepine (other than clonazepam) or baclofen. All of which are drugs that can cause 
sedation and general CNS depression, just like gabapentin, pregabalin and amitriptyline. 
Considering that fatigue is one of the most common MS symptoms affecting 75 % of patients 
(Hadjimichael et al. 2008), these pharmacodynamic interactions are likely to be clinically 
relevant. Such interactions may affect the patient’s reaction time and thus ability to drive or 
operate heavy machinery. The Norwegian Directorate of Health suggest halving the 
maximum dosages regarded as safe for driving when combining two drugs from their list of 
drugs that require attention (Helsedirektoratet 2006). The clinician’s assessment of the 
individual patient’s ability to drive supersedes the recommendations given by the guideline. 
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The applied recommendations of today limit the possibility of many of the included patients 
in the study to drive a car. A consideration of applying serum concentration measurements 
instead of dosage could adjust for extensive pharmacokinetic variability among patients. 
 
Pharmacokinetic variability  
Pharmacokinetic and pharmacodynamic interactions may be further potentiated by 
interindividual differences. Pharmacokinetic variability includes a number of important 
parameters that need to be considered in the individual patient. Genetic variations between 
individuals result in different capacity of enzyme activity which can alter clearance (Lesko 
and Schmidt 2012). Obesity may affect serum concentrations, as the volume of distribution of 
lipid-soluble drugs increases. Age changes physiological and thus pharmacokinetic 
parameters such as clearance and half-life. One third of the patients in the AED/TCA 
subpopulation were 60 years or older. These patients generally have lower renal clearance and 
may therefore require lower dosages. We know that the most commonly daily used AEDs, 
gabapentin and pregabalin, are unlikely to cause pharmacokinetic interactions partly because 
they are excreted renally. In patients with reduced renal clearance, however, they require 
attention and certainly when combined with other CNS-depressing drugs. If this is not 
considered, they are more likely to suffer from adverse reactions and pharmacodynamic 
interactions in particular. 
When physiological parameters vary greatly and therapeutic windows are small, as 
exemplified above, it is apparent that pharmacologic treatment should vary too. The 18-fold 
dosage variation described for pregabalin displays the wide range of variability. 
 
Treatment challenges and clinical implications 
Neuropathic pain is difficult to treat and central neuropathic pain, in particular. The drug 
distribution showed that 6.7 % of the patients in the AED/TCA subpopulation were using ten 
drugs or more and that 57 % of the patients were using five drugs or more. This elucidates the 
vast potential for polypharmacy issues, such as compliance, interactions and adverse 
reactions. Poor compliance may be caused by cognitive effects, which can be improved by a 
pill organiser or single-dose packing, or it may be intentional as a result of adverse reactions. 
Drug treatment may be initiated by the patient’s personal physician, personal neurologist or 
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MSSH’s neurologist and drug tapering may be difficult if treatment was initiated by another 
doctor.  
The pharmacologic treatment of MS patients today relies mainly on clinical observations. 
Baclofen dosages are finely tuned this way. Patients with spasms and highly limited leg 
muscle function may depend on the constriction of their leg muscles by the spasms to be able 
to stand. While it may be painful, it can still be of major importance to the patient. If this 
patient would use more baclofen she would lose the ability to stand. Whereas a patient 
permanently restricted to a wheelchair would prefer a much higher dosage, better relieving the 
painful spasms (Beiske 2013). 
In other disorders where therapeutic windows are narrow, measuring serum concentrations of 
the drugs is used as a tool for achieving optimal dosages; this is termed therapeutic drug 
monitoring (TDM). TDM is useful because achieving an individually optimal serum 
concentration is of vital importance when adverse reactions can be serious (Budde and 
Glander 2008). When antiepileptic drugs are used to treat epilepsy or psychiatric disorders, 
TDM is routinely utilised in Norway (Bengtsson 2004, Patsalos et al. 2008, Lesko and 
Schmidt 2012). Close monitoring of AEDs by implementation of therapeutic drug monitoring 
may control for pharmacokinetic variability and -interactions (Patsalos et al. 2008). This is 
also important to consider for psychotropic drugs, as it has been demonstrated that female 
gender and old age are important factors contributing to pharmacokinetic variability and 
lower serum concentrations of antidepressants (Waade et al. 2012). An alternative 
implementation of TDM is for example in immunosuppressive treatment with mycophenolate 
(Vethe et al. 2008). The increasing use of TDM has allowed for development of TDM 
databases which act as a reference for targeting serum concentrations, improving treatment 
and reducing adverse reactions. When applying the concept of an individual therapeutic 
concentration in the single patient, TDM could also be useful when these antiepileptic drugs 
are used in the treatment of neuropathic pain (Johannessen and Landmark 2008). 
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4.2 Discussion of method 
This study aimed to examine use of AEDs and TCAs in pharmacological treatment of pain in 
MS, in light of polypharmacy issues. Relating pharmacological treatment to patients’ degree 
of disability with a special focus on pain therapy is a new approach to apply current 
knowledge of evidence-based medicine for the benefit of MS patients. The method chosen, 
provided a relatively large population and the data was electronically available allowing 
efficient data gathering. A downside to retrospective studies of medical records is however, 
the lack of information in the medical records. An example of this in our study, proved to be 
the availability of EDSS scores. Only 343 of 869 medical records included an EDSS score. 
Every patient staying at MSSH is assigned an id number by the administration. There is no 
way to link the patient’s id number to their identity without access to the Extensor database. 
Therefore these id numbers were registered directly in the study spread sheet. The benefit of 
utilising MSSH’s patient id numbers was that there never was created a document which 
could identify the patient data. 
Examining prescriptions to a large population may also uncover new potential interactions, 
both pharmacodynamic and pharmacokinetic (Johannessen Landmark and Patsalos 2012). 
The importance of such aspects of these studies, are highlighted by the limitations of phase III 
clinical trials with regards to inclusion criteria and study duration. Both positive and negative 
results of this study may be utilised to benefit the patient population. 
The use of amitriptyline was defined as an inclusion criterion, since it is used frequently in 
treatment of neuropathic pain. AEDs were included regardless of their indication, because the 
link of increased epilepsy prevalence in MS adds another interesting aspect to the 
investigation of their use. Other TCAs than amitriptyline (e.g. TCAs not used for neuropathic 
pain) were not defined among these inclusion criteria. Data on the use of other TCAs were 
registered when coadministered with a drug on the list of inclusion criteria, in line with other 
concomitantly used drugs, but the extent of use was limited. 
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4.3 Future prospects and concluding remarks 
Future prospects 
Sativex was recently approved (28
th
 Nov 2012) for treatment of spasms in Norway, however, 
since no patients were using it in the inclusion period it was not discussed in great detail in 
this thesis. Cannabinoids have also been proven efficacious in MS related pain by vigorous 
studies, but their spectre of adverse reactions has yet to be fully determined and they have not 
been proven superior to other treatment options (Solaro and Uccelli 2011).  
Extending the study to include patients with a stay at MSSH in 2012 would be of value as it 
could address questions based on current results. Will the doubling of gabapentin 
prescriptions from 2010 to 2011 stabilise or keep increasing? Including 2012 in the study 
would also provide data on the use of the new drugs Sativex and Fampyra (fampridine). 
Fampyra is potassium channel blocker and more than 100 patients at MSSH used it in 2012. It 
is applied to improve walking distance in MS patients, however as its action on neurons is 
opposite of AEDs we suspect it may have an impact on pain treatment. 
 
Conclusion 
This study has shown that one third of MS patients used either an AED or TCA and that one 
fifth used two or more. There was no difference in age, gender or degree of disability of the 
patients using these drugs. Pain is a common and debilitating symptom and polytherapy is 
widespread, with up to 19 concomitant drugs in use. Although the AEDs are well-known for 
their pharmacokinetic interactions, this is not particularly concerning for MS patients since 
they mainly used newer AEDs (pregabalin and gabapentin) with little propensity to interact. 
Pharmacodynamic interactions are of greater concern seeing as more than half of the patients 
used an opioid, a benzodiazepine or baclofen in addition to their AED/TCA therapy. One 
third of the patients were elderly and careful considerations regarding pharmacokinetics and 
possible excessive adverse reactions are of importance. 
Applying therapeutic drug monitoring when using AEDs and TCAs for treatment of 
neuropathic pain is worth considering, seeing as it has been so valuable in treatment of 
epilepsy. To reduce the total drug load or dosages of CNS-active drugs may also be important 
in many patients. The results in this study add to the research on pharmacological treatment of 
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pain in MS and call for risk/benefit studies of pain treatment in light of pharmacodynamic 
interactions and interindividual variability.  
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